Encouraging Phase Ib Findings from Genentech on CT-388, a Dual GLP-1/GIP Receptor Agonist, in Individuals Battling Obesity
Genentech, a member of the Roche Group, disclosed favorable outcomes from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist aimed at addressing obesity and type 2…
SunLink Health Systems, Inc. Reveals Performance for Fiscal Q3 2024
SunLink Health Systems, Inc. (NYSE American: SSY) disclosed today a loss from continuing operations of $824,000 (equating to a loss of $0.12 per fully diluted share) for its third fiscal…
OmniAb Showcases xPloration® High-Throughput Single B-cell Screening Data at 20th Annual PEGS Boston Summit
OmniAb has announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, held at the Omni Hotel. Earlier today, the company presented an…
enGene Elects Paul Hastings and Wouter Joustra to its Board of Directors
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company with its lead non-viral program EG-70 undergoing pivotal trials for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced the election of…
Omeros Corporation Reports First Quarter 2024 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders such as…
Gate Neurosciences to Present New Synaptic Function Molecule Research at 2024 ASCP Annual Meeting
A clinical-stage biotechnology company focused on precision medicine to develop next-generation neuroscience therapies announced its upcoming activities at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP)…
UCSF, in Collaboration with Nutcracker Therapeutics, Unveils Groundbreaking Prostate Cancer Data at AAI 2024
Nutcracker Therapeutics, a biotechnology company focused on developing transformative RNA therapies through its proprietary technology platform, announced the presentation of key prostate cancer antigen research by its partners at the…
VBI Vaccines Reports First Quarter 2024 Financial Results
VBI Vaccines Inc. (Nasdaq: VBIV) Announces Q1 2024 Business Update and Financial Results VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company focused on immunology to develop potent disease prevention and…
Quarterly Update: Legend Biotech’s Performance and Recent Achievements in Q1 2024
Legend Biotech Corporation (NASDAQ: LEGN), a global pioneer in cell therapy, unveiled its unaudited financial performance for the first quarter of 2024 alongside notable corporate achievements. Dr. Ying Huang, CEO…
Incyte’s Plans to Repurchase Up to $2.0 Billion Worth of Its Common Stock
Incyte Corporation (Nasdaq:INCY) announced today that its Board of Directors has greenlit a $2.0 billion share repurchase program. As part of this initiative, the company has initiated a modified “Dutch…
Fycompa® Approved in China as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures
Eisai announced today that it has received approval in China for an additional indication of its antiepileptic drug (AED) Fycompa® (generic name: perampanel hydrate) for adjunctive treatment of primary generalized…
Zilucoplan Shows Significant Fatigue Improvement in gMG: Journal of Neurology Study
UCB, a global biopharmaceutical company, announced that the Journal of Neurology has published data from the Phase 3 RAISE study and the ongoing RAISE-XT open-label extension (OLE) study on the…